BE1006819A7 - Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. - Google Patents
Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. Download PDFInfo
- Publication number
- BE1006819A7 BE1006819A7 BE9300285A BE9300285A BE1006819A7 BE 1006819 A7 BE1006819 A7 BE 1006819A7 BE 9300285 A BE9300285 A BE 9300285A BE 9300285 A BE9300285 A BE 9300285A BE 1006819 A7 BE1006819 A7 BE 1006819A7
- Authority
- BE
- Belgium
- Prior art keywords
- prostheses
- treatment
- vessel
- stents
- chokes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Door het coaten van endovasculaire prothesen met amfifiele polyurethanen zijn wij erin geslaagd de biocompatibiliteit en de bloedcompatbiliteit van endovasculaire prothesen significant te verbeteren. Deze amfifiele polyurethanen hebben de eigenschap, wanneer ingeplant in menselijke of dierlijke weefsels en bloedvaten, stabiel te blijven en quasi geen inflammatoire reactie uit te lokken. Verder is het mogelijk medicijnen in deze polymeren te verwerken die na inplantatie van de polymeren langzaam zullen vrijkomen ter hoogte van de inplantatieplaats. Dit systeem kan de trombogeniciteit van de met polyurethanan gecoate prothesen nog verder doen afnemen en de afstootreactie tegen deze prothesen inhiberen.By coating endovascular prostheses with amphiphilic polyurethanes, we have succeeded in significantly improving the biocompatibility and blood compatibility of endovascular prostheses. These amphiphilic polyurethanes have the property, when implanted in human or animal tissues and blood vessels, to remain stable and to elicit virtually no inflammatory response. Furthermore, it is possible to incorporate drugs into these polymers which will slowly be released at the implantation site after the polymers have been implanted. This system can further decrease the thrombogenicity of the polyurethane-coated prostheses and inhibit the rejection response against these prostheses.
Description
<Desc/Clms Page number 1>
POLYURETHAAN-GECOATE PROTHESEN (STENTS) VOOR DE BEHANDELING VAN BLOEDVATVERNAUWINGEN. Een nieuwe methode om bloedvatvernauwingen te behandelen door middel van endovasculaire prothesen die bedekt worden (gecoat) met amfifiele polyurethanen waaraan medicijnen gekoppeld kunnen worden.
BESCHRIJVING Behandeling van bloedvatvernauwingen door middel van een balloncatheter is een populaire methode. Vorig jaar werden op deze manier in ans land meer dan 6000 patienten met coronaire bloedvatvernauwingen behandeld. Probleem van deze behandelingsmethode is enerzijds het gevaar dat tijdens it opblazen van de ballon een scheur ontstaat waardoor het bloedvat kan dichtvallen en alzo een akuut myocardinfarkt kan veroorzaken, anderzijds is het goed gedocumenteerd dat deze behandelingsmethode gepaard gaat met een frequente teruggroei (restenose) van de bloedvatvernauwing binnen de 6 maand na de behandeling. Om deze problemen optelossen werden enerzijds medicijnen uitgetest om de teruggroei van de vernauwing te voorkomen en anderzijds nieuwe behandelingsmethoden ontwikkeld.
Een van die nieuwe behandelingsmethoden bestaat erin een metalen intravasculaire prothese (stent) ter hoogte van de vernauwing te plaatsen. Deze methode is zeer efficient voor het behandelen van vaatscheuren die kunnen ontstaan tijdens de ballondilatatie maar deze metalen ondersteuningen zijn op zichzelf ook trombogeen en kunnen aanleiding geven tot een trombotische occlusie van het bloedvat. anderzijds bleek dat door het implanteren van een metalen prothese in een bloedvat het lichaam kan reageren met een afweerreactie waardoor terug bloedvatvernauwingen (restenose) kunnen ontstaan binnen de 6 maand'na implantatie van de prothese.
Vervolgens heeft men geprobeerd polymeer prothesen te maken maar ook deze gaven dezelfde problemen.
Door het bedekken (coaten) van deze endovasculaire prothesen met amfifiele polyurethanen zijn wij erin geslaagd zowel het probleem van de trombotische occluses als het probleem van de reactieve hyperproliferatieve response die aanleiding geeft tot restenose op belangrijke wijze te beperken. Deze polyurethanen worden gesynthetiseerd vertrekkend van amfifiele polyester-diolen op basis van ethyleenoxide en propylenoxide. Door reactie met een diosocyanaat en een ketenverlenger (butaandiol) wordt finaal een thermoplastisch polyurethaan bekamen. Door de geschikte keuze van a) het polyesterdiol, meer bepaald de verhouding ethyleenoxide/propyleenoxide, en b) het moleculair gewicht van het diol kan de bio- en bloedcompatibiliteit worden beinvioed.
Deze polyurethanen hebben de eigenschap, wanneer ingeplant in menselijke of dierlijke weefsels of in menselijke of dierlijke bloedvaten, stabiel te blijven en quasi geen inflammatoire reactie uit te lokken.
Deze polyurethanen bleken in onze dierexperimenten dan ook uitermate geschikt als coating van endovasculaire prothesen.
<Desc/Clms Page number 2>
Verder is het mogelijk om medicijnen aan deze polyurethanen te binden. Deze medicijnen hebben tot doel de trombogeniciteit van de prothesen nog verder te verminderen (heparin, hirudine, streptokinase, tpa e. a.) en de afstotingsreactie tegen de prothese nog verder te inhiberen (ACE remmers, corticoiden, angiopeptine, antimitotica e. a.).
TOEPASSINGSMOGELIJKHEDEN VAN HET SYSTEEM 1. Behandeling van bloedvatvernauwingen bij mens en dier.
2. Behandeling van complicaties ontstaan tijdens andere behandelingsmethoden van bloedvatvernauwingen.
3. Behandeling van complicaties ontstaan tijdens diagnostische procedures voor het opsporen van cardiale en vaataandoeningen.
4. Coating van prothesen, draden, en catheters ingebracht voor medische doeleinden.
<Desc / Clms Page number 1>
POLYURETHANE-COATED PROSTHESES (STENTS) FOR THE TREATMENT OF VESSEL STRENGTHS. A new method to treat vasoconstrictions using endovascular prostheses covered (coated) with amphiphilic polyurethanes to which drugs can be linked.
DESCRIPTION Treatment of blood vessel strictures by means of a balloon catheter is a popular method. Last year, more than 6,000 patients with coronary artery strictures were treated in this country. The problem of this treatment method is on the one hand the danger that during the inflation of the balloon a rupture occurs which can cause the blood vessel to close and thus cause an acute myocardial market, on the other hand, it is well documented that this treatment method is accompanied by a frequent regrowth (restenosis) of the blood vessel constriction within 6 months after treatment. To solve these problems, medicines were tested on the one hand to prevent the regrowth of the narrowing and on the other hand new treatment methods were developed.
One of these new treatment methods is to place a metal intravascular prosthesis (stent) at the level of the narrowing. This method is very efficient in treating vascular tears that may develop during balloon dilatation, but these metal supports are also thrombogenic in themselves and may lead to thrombotic occlusion of the blood vessel. on the other hand, it has been found that by implanting a metal prosthesis in a blood vessel, the body can react with an immune response, which can lead to blood vessel constrictions (restenosis) within 6 months after implantation of the prosthesis.
Subsequently, attempts were made to make polymer prostheses, but these also presented the same problems.
By covering (coating) these endovascular prostheses with amphiphilic polyurethanes, we have succeeded in significantly limiting both the problem of thrombotic occluses and the problem of the reactive hyperproliferative response that gives rise to restenosis. These polyurethanes are synthesized starting from amphiphilic polyester diols based on ethylene oxide and propylene oxide. A thermoplastic polyurethane is finally obtained by reaction with a diosocyanate and a chain extender (butanediol). By the suitable choice of a) the polyester diol, in particular the ratio ethylene oxide / propylene oxide, and b) the molecular weight of the diol, the bio and blood compatibility can be influenced.
These polyurethanes have the property, when implanted in human or animal tissues or in human or animal blood vessels, to remain stable and to elicit virtually no inflammatory response.
In our animal experiments, these polyurethanes were therefore extremely suitable as a coating for endovascular prostheses.
<Desc / Clms Page number 2>
It is also possible to bind medicines to these polyurethanes. These drugs aim to further reduce the thrombogenicity of the prostheses (heparin, hirudin, streptokinase, tpa e. A.) And to further inhibit the rejection reaction against the prosthesis (ACE inhibitors, corticoids, angiopeptin, antimitotics e. A.).
POSSIBILITIES OF APPLICATION OF THE SYSTEM 1. Treatment of blood vessel strictures in humans and animals.
2. Treatment of complications arising from other treatment methods of blood vessel strictures.
3. Treatment of complications arising during diagnostic procedures for the detection of cardiac and vascular disorders.
4. Coating of prostheses, wires, and catheters introduced for medical purposes.
Claims (1)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9300285A BE1006819A7 (en) | 1993-03-24 | 1993-03-24 | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. |
PCT/BE1994/000024 WO1994021309A1 (en) | 1993-03-24 | 1994-03-24 | Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis |
AU61780/94A AU6178094A (en) | 1993-03-24 | 1994-03-24 | Polyurethane-coated intravascular prostheses (stents) for the treatment of blood vessel stenosis |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9300285A BE1006819A7 (en) | 1993-03-24 | 1993-03-24 | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. |
Publications (1)
Publication Number | Publication Date |
---|---|
BE1006819A7 true BE1006819A7 (en) | 1994-12-13 |
Family
ID=3886925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE9300285A BE1006819A7 (en) | 1993-03-24 | 1993-03-24 | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU6178094A (en) |
BE (1) | BE1006819A7 (en) |
WO (1) | WO1994021309A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5980972A (en) * | 1996-12-20 | 1999-11-09 | Schneider (Usa) Inc | Method of applying drug-release coatings |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6776796B2 (en) | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
AU2001294869B2 (en) | 2000-09-29 | 2006-06-15 | Cardinal Health 529, Llc | Coated medical devices |
GB0100761D0 (en) * | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
US8182527B2 (en) | 2001-05-07 | 2012-05-22 | Cordis Corporation | Heparin barrier coating for controlled drug release |
US20060088571A1 (en) * | 2004-10-21 | 2006-04-27 | Medtronic Vascular, Inc. | Biocompatible and hemocompatible polymer compositions |
US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
EP2855030B1 (en) | 2012-06-01 | 2019-08-21 | SurModics, Inc. | Apparatus and method for coating balloon catheters |
DE102014201889A1 (en) | 2014-02-03 | 2015-08-20 | Aesculap Ag | Medical product for use in the treatment of hernias |
WO2020112816A1 (en) | 2018-11-29 | 2020-06-04 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS588700B2 (en) * | 1980-09-12 | 1983-02-17 | 工業技術院長 | Method for producing antithrombotic high modulus polyurethane compound |
DE3786721D1 (en) * | 1986-02-24 | 1993-09-02 | Fischell Robert | DEVICE FOR DETECTING BLOOD VESSELS AND SYSTEM FOR ITS INTRODUCTION. |
US5449372A (en) * | 1990-10-09 | 1995-09-12 | Scimed Lifesystems, Inc. | Temporary stent and methods for use and manufacture |
AU1579092A (en) * | 1991-02-27 | 1992-10-06 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
EP0566245B1 (en) * | 1992-03-19 | 1999-10-06 | Medtronic, Inc. | Intraluminal stent |
-
1993
- 1993-03-24 BE BE9300285A patent/BE1006819A7/en not_active IP Right Cessation
-
1994
- 1994-03-24 WO PCT/BE1994/000024 patent/WO1994021309A1/en active Application Filing
- 1994-03-24 AU AU61780/94A patent/AU6178094A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1994021309A1 (en) | 1994-09-29 |
AU6178094A (en) | 1994-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BE1006819A7 (en) | Polyurethane coated prostheses (stents) FOR THE TREATMENT OF VESSEL CHOKES. | |
BE1008260A6 (en) | Amphiphile polyurethane charged with medicine which is coated onto vascularstents for the treatment of blood vessel constriction | |
Wache et al. | Development of a polymer stent with shape memory effect as a drug delivery system | |
Schatz | A view of vascular stents. | |
Liermann et al. | The Strecker stent: indications and results in iliac and femoropopliteal arteries | |
US6203536B1 (en) | Medical device for delivering a therapeutic substance and method therefor | |
Ozaki et al. | New stent technologies | |
WO1998057706A1 (en) | An implantable device for delivering localized radiation in vivo and method for making the same | |
Tsuji et al. | Biodegradable polymeric stents | |
JP2009525809A (en) | Implantable medical device with drug delivery coating with surface erodible polyester | |
EP1673031A1 (en) | Polymeric reconstrainable, repositionable, detachable, percutaneous endovascular stentgraft | |
EP0691841B1 (en) | Medicament dispensing stents | |
JP2006500996A (en) | Apparatus and method for delivering mitomycin via an eluting biocompatible implantable medical device | |
WO2002069842A2 (en) | Apparatus and method for maintaining flow through a vessel or duct | |
Ellis et al. | Intracoronary stents: will they fulfill their promise as an adjunct to angioplasty? | |
US6746481B1 (en) | Implatable device including a polyamino acid component | |
Violaris et al. | Endovascular stents: a ‘break through technology’, future challenges | |
De Scheerder et al. | Intravascular low‐power laser irradiation after coronary stenting: Long‐term follow‐up | |
De Scheerder et al. | Concept of the homemade coronary stent: experimental results and initial clinical experience | |
BE1006816A7 (en) | Polyphosphazene-coated prosthesis (stents) for the treatment of blood vessel constriction | |
McKenna et al. | Novel stents for the prevention of restenosis | |
De Feyter et al. | Some thoughts on the present and future of coronary artery stenting. | |
BE1008668A6 (en) | A new endovascular prostheses (ids-sts-2) for the treatment of dissected andnarrowed blood vessels | |
US20090228097A1 (en) | A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device | |
Fajadet et al. | Coronary Stenting with the Palmaz-Schatz Stent: The Clinic Pasteur Interventional Cardiology Unit Experience |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RE | Patent lapsed |
Owner name: DSB N.V. Effective date: 19950331 |